2008.06.27 10:43 Stocks - Investing and trading for all
2011.05.09 05:00 misnamed Passive Indexing Community for Long-Term Lazy Investors
2012.06.17 20:13 Algorithmic Trading
2024.06.05 18:38 ConflictExpensive892 New scam
Haven't seen the scan where they actually email you before. submitted by ConflictExpensive892 to poshmarkcanada [link] [comments] |
2024.06.05 18:37 skuxy18 The Dark History of Naked Short Selling
In light of recent events, I highly recommend all apes, old and new to read this eye-opening article that transcribes the events of Naked Short selling and how they cull innovation and businesses since the 1980's. submitted by skuxy18 to Superstonk [link] [comments] link A brief lesson in historyIn the days of old, Wall Street created a system of exchanging shares via paper certificates. You would place an order to buy a share, your broker would send someone down to Wall Street, they purchase a share, and everything is accounted for.However, in the late 60's, a paperwork crisis emerged as this process was extremely inefficient. What does the government implement? The DTC and NSCC for clearance and settlement so that we may switch our inefficient process to an electronic one. Allowing trades to be completed instantaneously. Sounds great right? In theory, yes. But we left a gaping hole in the system. The Stock Borrow Programme. In this new system, we now had a lending pool of shares available. The buyer (you or me) would go to the broker to purchase a stock, the broker goes to the market-maker who short-sells them the stock, and the NSCC could pull the shares from the DTCs lending pool to speed up the transaction process. The broker would then have T+3 days to settle the trade (now T+1) or face a Failure-to-deliver (FTD). So what's the problem?The DTC failed to put in incentives for the brokers to pay back the borrowed stock.The brokers could take months or years to pay back the trade unless someone caught on and tried to pull every share on the market. And this would never happen. The result is a perfect system for manipulating and naked-short selling. Now, you have a system where there is an entire lending pool and the ability for market-makers to pull shares from the lending pool to loan to Broker A, B, or C. Creating multiples of more shares than exist in the float Self-Replenishing pool theory Now on to how this all works. Buyer A asks Broker A to purchase 1000 shares of Stock XYZ at $1 per share. Broker A goes to the Market-Maker with our $1k. Market-Maker confirms the purchase of the trade without locating the shares first! and fills the order. When the trade FTDs in T+1 because the MM has not located the shares, it reaches into DTCCs lending pool via stock borrow programme. The DTCC sees that share exist in Broker Bs account, and uses them to fill. But, Broker B got their shares from Investor Bs account. Now you have 2,000 shares. 1k in Buyer A's account and 1k in Investor Bs account. Reports suggest the DTCC does not keep track of how long these shares are lent out, so there is no pressure or cost to fill. Now with the CAT. We should get an audit trail to where these shares are. This is how more shares are able to trade and short stocks than actually exist. This is also why DRSing is crucial. How this played out in the real world.Hedge Funds catch on quickly, and begin shorting small-cap stocks which fly under the radar and are undervalued. Because there is an ability to create more shares than actually exist, Hedge Funds can take advantage of the slightest bad news, and short the stock over 100% of their float into oblivion.This causes a crisis of culling innovation in US markets. Microsoft, Dell, Oracle, and Cisco started as pink-sheet stocks. All companies that fit the bill of naked short selling for these hedge funds. What if they had been shorted into oblivion? How many other companies suffered that could have changed the world? What's next?GameStop baby. These fuckers are stuck bag-holding a company that is no longer going to $0. Their hail mary was doubling-down on the shorts after Jan 2021, and spreading misinformation that the stock was dying and that everyone should exit. Thanks to RC, DFV and you beautiful apes, we didn't fucking sell.Now they are stuck paying premiums out the ass for FTDs, on a company that is growing and will not go to $0. The result will be a squeeze as they have no option other than to buy back their shares on loan used for shorting eventually. They are losing money both on the FTDs and on naked shorts. The only two options are to:
TL:DR Naked-Short-Selling dates back as early as 1981. Thousands of US companies have been culled due to these illegal tactics by hedge-funds, allowed by a incomplete stock borrow programme. As a result, naked short selling has run rampant in US stock market history. GameStop is the first incident where we have a stock that will not go to $0, and a shit ton of eyes on the situation. This is no small-cap, under the radar stock anymore. The only outcome is a short-squeeze. |
2024.06.05 18:37 littlezappa Webull Canada Referral Code - Sign up and get a $50 Bonus when you fund atleast 100 dollars
2024.06.05 18:35 Maskekar [TH] 6.6 Flash Day for Slots
It’s raining cash! Get Mega Bonus of THB 750 when you play Slots!Join BK8 Now to be eligible! Event Details Details How to Apply
|
2024.06.05 18:33 mattschinesefood Customizing unisex clothing product from China (Alibaba) - getting started questions.
2024.06.05 18:32 mattschinesefood Customizing unisex clothing product from China (Alibaba) - getting started questions.
2024.06.05 18:32 Syndicate_Corp 401k - Fidelity FBCGX - Price reporting issue
2024.06.05 18:16 Comfortable_Pay_2582 Does it make sense to have a non-retirement brokerage account?
2024.06.05 18:14 littlezappa Join Wealthsimple and Get a Bonus ($25 for you and $25 for me) or (Up to $250 for Premium or $1000 for Generation) Including Previous Non Referred Members 🍁
2024.06.05 18:09 MightBeneficial3302 NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)
submitted by MightBeneficial3302 to Wealthsimple_Penny [link] [comments] https://preview.redd.it/ssj9aa2x1s4d1.png?width=300&format=png&auto=webp&s=65a900abd2aa90a39d2a8aacfaa0facfaa3a917d NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce its financial and operational results for the three months ended March 31, 2024, the highlights of which are included in this news release. The Company’s full set of consolidated financial statements for the three months ended March 31, 2024, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.nurexone.com and its profile page on SEDAR+ at www.sedarplus.ca. Key Business Highlights On March 1, 2024, the Company commenced the setup of in-house laboratories and offices to bolster its research and development capabilities, subsequent to entering into lease and construction agreements. Completion of these initiatives is anticipated by the end of June 2024. On March 22, 2024, the Company completed the acceleration of 12,682,340 warrants issued pursuant to a private placement of units that closed on June 15, 2022. Following the acceleration event, the Company received gross proceeds of US$2.92 million (approximately C$4.0 million) from the exercise of 10,423,629 common share purchase warrants, which represented accelerated and non-accelerated warrants of which 9,684,993 warrants were exercised at a price of C$0.38, 556,818 warrants were exercised at a price of C$0.34, and 181,818 warrants were exercised at a price of C$0.48. The Company exercised its right to accelerate the expiry date of certain warrants to thirty days upon the Company’s common shares exceeded C$0.475 for ten consecutive trading days on the TSX Venture Exchange (“TSXV”). “We appreciate the confidence of the investors who exercise their warrants, and the ongoing support of NurExone’s journey,” stated Eran Ovadya, NurExone Chief Financial Officer. On April 1, 2024, the Company entered into a Contract Research Organization services agreement with Vivox Ltd. for animal experiments as part of the preclinical testing phase for the submission of an Investigational New Drug (“IND”) application to the United States Food and Drug Administration (the “FDA”). This is aimed at assessing the safety and efficacy of the ExoPTEN drug before proceeding to clinical trials involving human subjects, which are anticipated to commence in 2025. This engagement followed the completion of a Pre-IND meeting with the FDA regarding the manufacturing, preclinical, and clinical development plan of ExoPTEN, NurExone’s inaugural ExoTherapy product, and the subsequent receipt of a written response from the FDA. On April 25, 2024, NurExone successfully secured approval for listing on the OTCQB Venture Market, marking a significant milestone in the Company's growth and visibility within the financial community, including in the USA. In addition, the Company achieved Depository Trust Company eligibility, which enhances the efficiency and cost-effectiveness of trading NurExone shares, facilitating better liquidity and broader access for investors. Growth Outlook for 2024 According to Chief Executive Officer Dr. Lior Shaltiel, “NurExone is committed to pioneering transformations in the field of regenerative medicine with new, minimally invasive therapies and we are moving along the regulatory path towards human trials for our first product, ExoPTEN. Our focus remains on enhancing our ExoTherapy platform for the production of nanodrugs, expanding our intellectual property, and forging strategic collaborations. Towards this end, we have recently engaged Dr. Ram Petter, Vice President and head of Bio Strategy at Teva Pharmaceutical, to support our efforts in collaborating with biopharma companies.” First Quarter Fiscal 2024 Financial Results
The Company had an accumulated deficit of US$14.98 million as of March 31, 2024, (December 31, 2023 - US$14.06 million). Eran Ovadya, NurExone’s Chief Financial Officer, added: “The Company maintains a strong cash position, ensuring sufficient funding until year-end. With strategic oversight, we navigate our business plan amidst ongoing activities, positioning ourselves for sustained growth and continued success.” About NurExone Biologic Inc. NurExone Biologic Inc. is a TSXV listed pharmaceutical company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications. For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube. For more information, please contact: Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: info@nurexone.com Thesis Capital Inc. Investment Relation - Canada Phone: +1 905-347-5569 Email: IR@nurexone.com Dr. Eva Reuter Investment Relation - Germany Phone: +49-69-1532-5857 Email: e.reuter@dr-reuter.eu |
2024.06.05 18:09 MightBeneficial3302 NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)
submitted by MightBeneficial3302 to 10xPennyStocks [link] [comments] https://preview.redd.it/skjldluv1s4d1.png?width=300&format=png&auto=webp&s=703ab35b18988abdd8254bc99f308cc1ad824f32 NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company developing regenerative medicine therapies, is pleased to announce its financial and operational results for the three months ended March 31, 2024, the highlights of which are included in this news release. The Company’s full set of consolidated financial statements for the three months ended March 31, 2024, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.nurexone.com and its profile page on SEDAR+ at www.sedarplus.ca. Key Business Highlights On March 1, 2024, the Company commenced the setup of in-house laboratories and offices to bolster its research and development capabilities, subsequent to entering into lease and construction agreements. Completion of these initiatives is anticipated by the end of June 2024. On March 22, 2024, the Company completed the acceleration of 12,682,340 warrants issued pursuant to a private placement of units that closed on June 15, 2022. Following the acceleration event, the Company received gross proceeds of US$2.92 million (approximately C$4.0 million) from the exercise of 10,423,629 common share purchase warrants, which represented accelerated and non-accelerated warrants of which 9,684,993 warrants were exercised at a price of C$0.38, 556,818 warrants were exercised at a price of C$0.34, and 181,818 warrants were exercised at a price of C$0.48. The Company exercised its right to accelerate the expiry date of certain warrants to thirty days upon the Company’s common shares exceeded C$0.475 for ten consecutive trading days on the TSX Venture Exchange (“TSXV”). “We appreciate the confidence of the investors who exercise their warrants, and the ongoing support of NurExone’s journey,” stated Eran Ovadya, NurExone Chief Financial Officer. On April 1, 2024, the Company entered into a Contract Research Organization services agreement with Vivox Ltd. for animal experiments as part of the preclinical testing phase for the submission of an Investigational New Drug (“IND”) application to the United States Food and Drug Administration (the “FDA”). This is aimed at assessing the safety and efficacy of the ExoPTEN drug before proceeding to clinical trials involving human subjects, which are anticipated to commence in 2025. This engagement followed the completion of a Pre-IND meeting with the FDA regarding the manufacturing, preclinical, and clinical development plan of ExoPTEN, NurExone’s inaugural ExoTherapy product, and the subsequent receipt of a written response from the FDA. On April 25, 2024, NurExone successfully secured approval for listing on the OTCQB Venture Market, marking a significant milestone in the Company's growth and visibility within the financial community, including in the USA. In addition, the Company achieved Depository Trust Company eligibility, which enhances the efficiency and cost-effectiveness of trading NurExone shares, facilitating better liquidity and broader access for investors. Growth Outlook for 2024 According to Chief Executive Officer Dr. Lior Shaltiel, “NurExone is committed to pioneering transformations in the field of regenerative medicine with new, minimally invasive therapies and we are moving along the regulatory path towards human trials for our first product, ExoPTEN. Our focus remains on enhancing our ExoTherapy platform for the production of nanodrugs, expanding our intellectual property, and forging strategic collaborations. Towards this end, we have recently engaged Dr. Ram Petter, Vice President and head of Bio Strategy at Teva Pharmaceutical, to support our efforts in collaborating with biopharma companies.” First Quarter Fiscal 2024 Financial Results
The Company had an accumulated deficit of US$14.98 million as of March 31, 2024, (December 31, 2023 - US$14.06 million). Eran Ovadya, NurExone’s Chief Financial Officer, added: “The Company maintains a strong cash position, ensuring sufficient funding until year-end. With strategic oversight, we navigate our business plan amidst ongoing activities, positioning ourselves for sustained growth and continued success.” About NurExone Biologic Inc. NurExone Biologic Inc. is a TSXV listed pharmaceutical company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications. For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube. For more information, please contact: Dr. Lior Shaltiel Chief Executive Officer and Director Phone: +972-52-4803034 Email: info@nurexone.com Thesis Capital Inc. Investment Relation - Canada Phone: +1 905-347-5569 Email: IR@nurexone.com Dr. Eva Reuter Investment Relation - Germany Phone: +49-69-1532-5857 Email: e.reuter@dr-reuter.eu |
2024.06.05 18:07 Life_Researcher4882 EVERYONE with FFIE Must Do THIS NoW…..
Everyone should do this right now! Just went to the SEC.gov and went to CONTACT Section. and wrote every commissioner the following email. submitted by Life_Researcher4882 to FFIE [link] [comments] Dear SEC Officials, My name is James, and I am writing to bring to your attention a series of illegal practices occurring against the stock FFIE (Faraday Futures) over the past several weeks. The frequency and magnitude of these actions have become alarming and are impossible to overlook. I am in the process of compiling a comprehensive report detailing each instance of these illegal activities, which appear to be perpetrated by certain hedge funds and other entities. This report will be made public to ensure transparency and accountability. The evidence is overwhelming and easily accessible to anyone who invests even a few moments to investigate. I have a substantial online following of over 600,000 individuals who deserve to know the truth about the corruption impacting retail investors. While I understand the SEC’s role in regulating the industry, the blatant nature of these activities cannot be ignored any longer. The retail investor community is counting on you to uphold market integrity and fairness. Please take immediate action to investigate and halt these corrupt practices. The trust and confidence of retail investors are at stake, and we deserve better than this…. Thank you for your attention to this critical matter! |
2024.06.05 18:05 hivincentc What's happening in the markets: June 5th
2024.06.05 18:03 mwaddmeplz Thank you MK Sharren Haskel
2024.06.05 17:36 J_R_D_N Shorts have passed the event horizon
Some of you still believe shorts will be able to escape this either by their continued illegal tactics or by staging some event they can blame this on. submitted by J_R_D_N to Superstonk [link] [comments] They will play dirty. They will stomp and shout claiming manipulation, but there is nothing they can do... Roaring Kitty (RK) has significantly increased his holdings over the past 3 years, now with cash on hand equal to his total portfolio in April 2021. His portfolio has seen a 525% increase. RK meticulously follows stock and market trends, leveraging options volatility arbitrage strategies to build his position. He was likely behind the significant options moves in late April and early May, strategically planning his return to coincide with meme tweets to create a positive feedback loop. RK's hands are clean. He is playing according to their rules within this "fair" market. Shout out to Peruvian Bull for his explanation on thishttps://www.reddit.com/Superstonk/comments/1d7y5t0/peruvial_bulL_on_roaring_kitty_calls_hes_building/ Roaring Kitty's position is acting as a “call wall”. Not being able to suppress the price, market makers HAVE to buy the underlying stock to hedge their risk, which drives up the stock price. This forces shorts to perpetually hedge to stay alive. https://preview.redd.it/ewmsbg3x4r4d1.png?width=561&format=png&auto=webp&s=b6dde2b758ddba0e14d39af578ef17f05556b65f The SEC’s CAT system’s Compliance Go-Live date was May 31, 2024. If you dont know by now, this system tracks all order and trading activity in the U.S. markets, enhancing oversight and transparency. This is over 10 YEARS in the making and you are telling me the CAT deployment coincides with Roaring Kitty’s resurgence and significant call option buys??? Industry Recommendations for the Creation of a Consolidated Audit Trail (CAT) dated: March 28, 2013 It is fully plausible that the SEC and DOJ have been in communication with Roaring Kitty for some time, ensuring they have the proper oversight tools to catch market manipulation by MM's and hedge funds. https://preview.redd.it/ledyrel5nr4d1.png?width=828&format=png&auto=webp&s=dccfe58fbd9c92b1e4616fe4bba024337e88df4b His return, while strategically timed, will continue to expose vulnerabilities that have always existed. We have already won. Edit: Just saw this Gary Gensler on MSMBC discussing market regulation with the Rat 6/5/24 "The SEC runs a civil law enforcement agency and you expect us to investigate where we investigate but we dont talk about it publicly.." "Public disclosure is really important to our Capital Markets" - Gary Gensler |
2024.06.05 17:27 Exotic_Sector7410 What are the most trusted proprietary trading firms for traders in 2024?
2024.06.05 17:26 Smok3dSalmon Jim Cramer appreciation post
2024.06.05 17:23 Exotic_Sector7410 What are the main books required to master the trading and investing?
2024.06.05 17:23 seemsdicey Please Audit our Investment Strategy. Wife (36YO) Me (35YO)
2024.06.05 17:19 jjdewit Deriv.com Broker Review: A Full Guide By A Seasoned Trader
2024.06.05 17:12 ThielschATX [HIRING] Entry-Level Field Engineer - Austin
2024.06.05 17:10 ThielschATX [HIRING] Entry-Level Field Engineer